Navidea Biopharmaceuticals Inc.
425 Metro Place North, Suite 450
Dublin, OH 43017
USA
Product Categories:
Radiology Imaging
Radiology Imaging
RELATED CONTENT
Navidea Biopharmaceuticals announced the completion of the sale of its Lymphoseek product to Cardinal Health. Navidea received approximately $83 million at closing, and will have the opportunity to earn up to $227 million of contingent consideration based on certain milestones through 2026, with $17.1 million of that amount guaranteed over the next three years.
March 08, 2017 
Navidea Biopharmaceuticals Inc. announced that it has executed a Letter of Intent (LOI) with Cardinal Health for the sale of all rights, title and interest to Navidea’s Lymphoseek product. The agreement covers all U.S. Food and Drug Administration (FDA)-approved, pending and future oncology diagnostic indications in North America, subject to certain limitations, as well as certain other related assets. Under the terms of the LOI, Navidea would receive $80 million at closing, with future consideration tied to annual sales of the Lymphoseek product and certain sales-based milestones. Total consideration to Navidea would be capped at $310 million.
September 06, 2016 
Navidea Biopharmaceuticals Inc. announced results from three investigator-initiated studies of the Lymphoseek injection at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 11-15 in San Diego.
July 06, 2016 
Navidea Biopharmaceuticals Inc. last week announced that the first patient has been enrolled in a clinical study evaluating Lymphoseek (technetium Tc 99m tilmanocept) injection in women with known cervical cancer.
February 18, 2016 
News | Oncology Diagnostics
Navidea Biopharmaceuticals Inc. announced that results from an investigator-initiated imaging study demonstrated Lymphoseek (technetium Tc 99m tilmanocept) injection reduced imaging time by more than 50 percent in sentinel lymph node biopsy procedures in malignant melanoma compared to Tc99m sulfur colloid (SC).
December 11, 2015 
Navidea Biopharmaceuticals Inc. received initial notice of award for a Fast Track Small Business Innovation Research (SBIR) grant up to $1.8 million from the National Cancer Institute (NCI), National Institutes of Health (NIH). The grant will be used to fund preclinical studies examining the safety of intravenous (IV) injection of Tc99m tilmanocept, a Manocept platform product.
September 03, 2015 
August 20, 2015 — Navidea Biopharmaceuticals announced publication of the results from an investigator-initiated ...
August 20, 2015 
Navidea Biopharmaceuticals Inc. announced plans to move forward with a joint study of the ability of Tc99m-tilmanocept, a Manocept platform product, to localize in high-risk atherosclerotic plaques. The study — funded through a $321,000 Phase 1 Small Business Innovation Research (SBIR) grant from the National Heart, Lung and Blood Institute (NHLBI), National Institute of Health (NIH) — will be conducted with Massachusetts General Hospital (MGH) and Harvard Medical School.
July 30, 2015 
News | Molecular Imaging
Navidea Biopharmaceuticals announced that results from several pre-clinical Manocept studies in rheumatoid arthritis (RA) were presented at the EULAR 2015 European Congress of Rheumatology in Rome, Italy from June 10-13, 2015. The results of studies, led by Wael Jarjour, M.D., Thomas J. Rosol, Ph.D., and Larry S. Schlesinger, M.D., of The Ohio State University Wexner Medical Center, highlighted the potential of CD206-targeting Manocept constructs to detect immune-mediated inflammation in RA ,which could be used diagnostically to monitor therapeutic efficacy or as a potential therapeutic platform.
June 26, 2015 News
Navidea Biopharmaceuticals announced that results from an investigator-initiated, comparative study of Lymphoseek (technetium Tc-99m tilmanocept) injection versus filtered Tc-99m Sulfur Colloid (fTcSC) were presented at the 2015 Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference. The study measured injection site pain in patients with breast cancer undergoing lymphoscintigraphy. Results of the randomized, double-blinded trial — led by Anne Wallace, M.D., professor of surgery at University of California, San Diego School of Medicine — highlighted that fTcSC caused statistically significant greater levels of pain after injection compared to Lymphoseek.
June 09, 2015 